Reuters logo
BRIEF-CymaBay Therapeutics initiates its next mid-stage study of seladelpar in patients with primary biliary cholangitis
December 7, 2016 / 1:30 PM / a year ago

BRIEF-CymaBay Therapeutics initiates its next mid-stage study of seladelpar in patients with primary biliary cholangitis

Dec 7 (Reuters) - CymaBay Therapeutics Inc -

* Study is designed to enroll approximately 36 patients in U.S., Canada, Germany and U.K.

* CymaBay Therapeutics announces the initiation of its next phase 2 study of seladelpar (mbx-8025) in patients with primary biliary cholangitis

* Study includes extension phase where patients will be able to continue treatment for 26 weeks

* Primary endpoint will be change in alkaline phosphatase (alp) Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below